Alfuzosin Hydrochloride Tablets

Alfuzosin hydrochloride is a quinazoline derivative that can selectively block postsynaptic alpha-adrenaline receptors distributed in the bladder, urethra, and prostate triangle, antagonizing the receptor-mediated contraction of the lower urinary tract smooth muscle, thereby improving the symptoms of dysuria in patients with benign prostatic hyperplasia.

The main ingredient of this product is alfuzosin hydrochloride.

This product is a white film-coated tablet, which appears white or off-white after the film coating is removed.

Used to relieve symptoms of benign prostatic hyperplasia.

Oral administration, it is recommended that the first dose be taken before bedtime. The usual dose for adults is 1 tablet (2.5 mg) 3 times a day. The starting dose for elderly patients is 1 tablet each morning and evening, and the maximum dose is 4 tablets (10 mg) a day. Patients with renal impairment: The starting dose should be 1 tablet (2.5 mg) 2 times a day, and then the dose should be adjusted according to clinical response. Patients with mild and moderate liver impairment: The starting dose should be 1 tablet (2.5 mg) 1 time a day, and then increased to 1 tablet 2 times a day according to clinical response.

Common adverse reactions include dizziness, weakness, headache, rapid heartbeat, and occasionally postural hypotension, hot flashes, drowsiness, indigestion, nausea, vomiting, diarrhea, syncope, dry mouth, and rash. If adverse reactions occur, please inform your doctor immediately.

1. Patients who are allergic to this product are prohibited from using this product. 2. Patients with low blood pressure and postural hypotension are prohibited from using this product. 3. Patients with severe liver damage are prohibited from using this product. 4. Children and women are prohibited from using this product.

Precautions for children: Forbidden to be taken by children Precautions for pregnant and lactating women: Forbidden to be taken by women Precautions for the elderly: The starting dose should be 1 tablet (2.5 mg) in the morning and evening, which can be increased to a maximum of 4 tablets (10 mg) per day.

1. This product should be avoided in combination with other alpha receptor antagonists; 2. Calcium antagonists and this product have a synergistic effect on vasodilation. Combination with this product may cause severe hypotension, so this product should be avoided in combination with calcium antagonists; 3. This product should be used with caution when used in combination with antihypertensive drugs and angina pectoris drugs.

Keep sealed.

2.5mg

24 months

CSPC OUYI Pharmaceutical Co., Ltd.

• Founded in:

  2001-03-29

• Address:

  No. 88, Yangzi Road, Shijiazhuang Economic and Technological Development Zone

• Tax NO.:

  91130100601289268L

• Registered Funds:

  298 million yuan

• Website:

  Log in to view

• Email:

  Log in to view